Amendment116th Congress
An amendment numbered 7 printed in Part B of House Report 116-334 to require an HHS study to identify conditions without an FDA-approved treatment where the development of a treatment would fill an unmet medical need for a serious or life-threatening condition or rare disease. Requires HHS to identify appropriate incentives that would lead to the development of such treatments.
- Amendment Number
- 717
- Description
- An amendment numbered 7 printed in Part B of House Report 116-334 to require an HHS study to identify conditions without an FDA-approved treatment where the development of a treatment would fill an unmet medical need for a serious or life-threatening condition or rare disease. Requires HHS to identify appropriate incentives that would lead to the development of such treatments.
- Purpose
- Amendment requires an HHS study to identify conditions without an FDA-approved treatment where the development of a treatment would fill an unmet medical need for a serious or life-threatening condition or rare disease. Also, the amendment requires HHS to identify appropriate incentives that would lead to the development of such treatments.
- Congress
- 116
- Type
- HAMDT
- Latest Action Date
- Dec 12, 2019
- Latest Action Text
- On agreeing to the Gottheimer amendment (A007) Agreed to by recorded vote: 380 - 45 (Roll no. 678).
- Latest Action Time
- 13:30:40
- Submitted Date
- Dec 12, 2019
- Chamber
- House of Representatives
- Update Date
- Feb 8, 2022